NEW YORK (GenomeWeb) – Juno Therapeutics and Editas Medicine today announced an exclusive collaboration to create chimeric antigen receptor (CAR) T cells and high-affinity T-cell receptor (TCR) cancer therapies.

The firms will pursue three research programs combining Editas' genome editing technologies, including CRISPR/Cas9, with Juno's immunotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.